166480.KQ CORESTEM Inc
- Market cap
- KRW 78.7B
- P/E
- -
- P/B
- 1.77x
- ROE
- -47.8%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 166480.KQ undervalued?
Graham numberThe Graham number of CORESTEM Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CORESTEM Inc fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-47.8%), below 10%.
ROA 0/1
Return on assets (-20.4%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (46.2%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 24.2% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (19.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.8x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
CORESTEM Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and ce…
Full company profileCORESTEM Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CORESTEM Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.0B | 18.1B | 22.3B | 24.3B | 26.4B | 30.2B | 46.3B | 33.7B | 28.8B | 20.2B | 19.5B |
| Gross Profit | 5.21B | 3.47B | 4.25B | 4.94B | 4.95B | 7.99B | 15.6B | 3.49B | -1.12B | -4.07B | -3.40B |
| Operating Income | -1.62B | -5.07B | -4.02B | -5.09B | -7.01B | -10.5B | -7.63B | -21.6B | -20.3B | -21.2B | -20.5B |
| EBITDA | - | - | - | - | - | - | 13.5B | -9.03B | -22.0B | -21.0B | -17.2B |
| Net Income | -1.66B | -4.01B | -3.40B | -5.17B | -23.2B | -7.00B | -2.66B | -17.7B | -26.3B | -26.8B | -21.2B |
| EPS | -106 | -255 | -216 | -329 | -1,475 | -441 | -124 | -825 | -1,038 | -558 | -442 |
| Balance Sheet | |||||||||||
| Total Assets | 85.7B | 90.7B | 89.3B | 85.6B | 143B | 136B | 78.6B | 78.6B | 117B | 112B | 104B |
| Total Liabilities | 19.0B | 25.1B | 27.0B | 28.0B | 102B | 99.2B | 37.2B | 59.0B | 68.9B | 57.2B | 59.6B |
| Shareholders' Equity | 66.7B | 65.6B | 62.2B | 57.7B | 41.3B | 37.2B | 41.5B | 19.6B | 48.6B | 55.2B | 44.4B |
| Cash & Short-term Investments | 49.6B | 40.2B | 39.0B | 30.7B | 93.5B | 68.7B | 2.59B | 2.71B | 3.49B | 2.34B | 4.44B |
| Total Debt | - | 1.21B | - | - | 4.40B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.50B | -6.29B | -1.13B | -538M | 4.47B | -7.65B | -8.42B | -15.7B | -21.1B | -13.9B | -7.87B |
| Capital Expenditure | 5.26B | 10.7B | 3.06B | 3.82B | 5.00B | 15.0B | 9.91B | 9.27B | 23.0B | 2.06B | 1.33B |
| Free Cash Flow | - | - | - | - | -553M | -23.9B | -18.3B | -25.0B | -44.2B | -15.9B | -9.21B |
| Ratios | |||||||||||
| ROE | -2.5% | -6.1% | -5.5% | -9.0% | -56.2% | -18.8% | -6.4% | -90.2% | -54.0% | -48.6% | -47.8% |
| ROA | -1.9% | -4.4% | -3.8% | -6.0% | -16.2% | -5.1% | -3.4% | -22.5% | -22.4% | -23.9% | -20.4% |
| Net Profit Margin | -9.3% | -22.1% | -15.2% | -21.3% | -88.0% | -23.1% | -5.7% | -52.5% | -91.3% | -133.1% | -109.0% |
| Debt to Equity | - | 0.02x | - | - | 0.11x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CORESTEM Inc dividends
CORESTEM Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2827:2297 on Sep 17, 2025.
Who owns CORESTEM Inc
- Insiders 9.74%
- Institutions 0.13%
- Public & others 90.12%
- Shares outstanding 48.1M
- Free float 42.6M
CORESTEM Inc company profile
- Company name
- CORESTEM Inc
- Ticker
- 166480.KQ
- ISIN
- KR7166480004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 289
- Fiscal year end
- December
- Address
- 24 Pangyo-ro 255beon-gil, Seongnam-si, South Korea, 13486
- Phone
- 82 2 497 3711
- Website
- corestem.com
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
CORESTEM Inc management
1- Ms. Kyung-Suk KimChief Executive Officer · born 1965